Meu SciELO
Serviços Personalizados
Journal
Artigo
Indicadores
Citado por SciELO
Acessos
Links relacionados
Citado por Google
Similares em SciELO
Similares em Google
Compartilhar
Farmacia Hospitalaria
versão On-line ISSN 2171-8695versão impressa ISSN 1130-6343
Resumo
PERICAY, C. et al. Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer. Farm Hosp. [online]. 2014, vol.38, n.4, pp.317-327. ISSN 2171-8695. https://dx.doi.org/10.7399/FH.2014.38.4.7631.
Objectives: To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin. Methods: Based on clinical trial VELOUR results, a three-state Markov model (stable disease, progression and death) with 2-week cycle duration was designed. Transition to health state "progression" implied the interruption of second-line treatment and administration of a third-line treatment (post-second line chemotherapy). Cost estimation included disease management cost (pharmaceutical, adverse event management, administration costs, etc.). Both cost and outcomes were discounted (3% annually). Sensitivity analyses (SA) were performed to test model robustness. Results: Administration of aflibercept + FOLFIRI as second-line treatment provided 1.78 LYG (21 life-months gained). With FOLFIRI 1.43 LYG (17 months) were obtained. The cost of the clinical management of aflibercept + FOLFIRI implied an additional investment of € 13,564 compared with FOLFIRI for a lifetime horizon, being total costs for aflibercept + FOLFIRI of € 38,346, compared to € 24,782 with FOLFIRI. In the cost-effectiveness analysis € 38,931/LYG was obtained with aflibercept in combination with FOLFIRI versus FOLFIRI. Conclusion: Aflibercept in combination with FOLFIRI increased overall survival versus FOLFIRI, so it is an effective strategy in the treatment of patients with mCRC. Aflibercept in combination with FOLFIRI is an efficient strategy for second-line mCRC treatment from the National Health System perspective.
Palavras-chave : Aflibercept; Cancer; Colorectal; Metastasis; Cost-effectiveness.